Flagship Harbor Advisors LLC Purchases 97 Shares of Danaher Co. (NYSE:DHR)

Flagship Harbor Advisors LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 1.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,783 shares of the conglomerate’s stock after purchasing an additional 97 shares during the quarter. Flagship Harbor Advisors LLC’s holdings in Danaher were worth $2,108,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in DHR. AM Investment Strategies LLC raised its holdings in Danaher by 1.5% during the first quarter. AM Investment Strategies LLC now owns 2,728 shares of the conglomerate’s stock worth $687,000 after buying an additional 41 shares during the last quarter. M&R Capital Management Inc. boosted its position in Danaher by 0.5% during the first quarter. M&R Capital Management Inc. now owns 9,011 shares of the conglomerate’s stock worth $2,271,000 after purchasing an additional 42 shares during the period. Silver Oak Securities Incorporated increased its stake in shares of Danaher by 4.3% in the first quarter. Silver Oak Securities Incorporated now owns 1,013 shares of the conglomerate’s stock worth $255,000 after purchasing an additional 42 shares in the last quarter. Bank Pictet & Cie Asia Ltd. increased its stake in shares of Danaher by 1.9% in the fourth quarter. Bank Pictet & Cie Asia Ltd. now owns 2,396 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 44 shares in the last quarter. Finally, Lathrop Investment Management Corp increased its stake in shares of Danaher by 2.2% in the first quarter. Lathrop Investment Management Corp now owns 2,050 shares of the conglomerate’s stock worth $517,000 after purchasing an additional 45 shares in the last quarter. 76.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent analyst reports. Bank of America boosted their price objective on shares of Danaher from $250.00 to $280.00 in a research note on Wednesday, July 26th. StockNews.com initiated coverage on shares of Danaher in a research note on Tuesday, September 12th. They set a “hold” rating for the company. Barclays boosted their price target on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 25th. Stifel Nicolaus cut their price target on shares of Danaher from $250.00 to $240.00 and set a “hold” rating for the company in a research note on Wednesday, July 26th. Finally, Royal Bank of Canada boosted their price target on shares of Danaher from $260.00 to $292.00 in a research note on Wednesday, July 26th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $289.79.

Insider Activity

In related news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction on Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the transaction, the senior vice president now owns 6,939 shares in the company, valued at approximately $1,738,497.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, SVP Jose-Carlos Gutierrez-Ramos sold 590 shares of Danaher stock in a transaction on Monday, August 21st. The shares were sold at an average price of $250.54, for a total transaction of $147,818.60. Following the transaction, the senior vice president now owns 6,939 shares in the company, valued at approximately $1,738,497.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Teri List sold 3,490 shares of Danaher stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $263.30, for a total transaction of $918,917.00. Following the transaction, the director now owns 17,494 shares in the company, valued at approximately $4,606,170.20. The disclosure for this sale can be found here. Insiders sold a total of 47,922 shares of company stock valued at $12,552,233 in the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.7 %

Shares of Danaher stock opened at $255.25 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.08 and a quick ratio of 1.70. Danaher Co. has a 1 year low of $221.22 and a 1 year high of $283.63. The firm has a market cap of $188.46 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 2.72 and a beta of 0.80. The company has a 50-day moving average of $253.41 and a 200 day moving average of $245.09.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 25th. The conglomerate reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.04. Danaher had a net margin of 20.95% and a return on equity of 15.03%. The firm had revenue of $7.16 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the previous year, the firm posted $2.76 EPS. The company’s revenue for the quarter was down 7.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Co. will post 8.84 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, October 12th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Wednesday, October 11th. Danaher’s payout ratio is 12.68%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions.